HomeMarketsSharesImmunocore Holdings plc

Trade Immunocore Holdings plc - IMCR CFD

27.7-0.11%
The chart shows the IMCR stock price data over the last 1 day, with a current price of 27.99, a high of 27.68, and a low of 27.46.
Low: 27.46High: 27.68
Sellers:
50%
Buyers:
50%
Past performance is not a reliable indicator of future results. Share prices are indicative and may differ from live market prices.
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.29
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.02235 %
(-$0.45)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


-0.02235%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
$1,000.00
Overnight funding adjustment
Charges from full value of position
0.00012 %
($0.00)

Trade size with leverage ~ $2,000.00

Money from leverage ~ $$1,000.00


0.00012%
Overnight funding adjustment time22:00 (UTC)
CurrencyUSD
Min traded quantity0.1
Margin50.00%
Stock exchangeUnited States of America
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close27.73
Open27.46
1-Year Change-24.79%
Day's Range27.46 - 27.68

Trade Immunocore Holdings plc - IMCR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. Its other programs for oncology comprise IMC-C103C that is in Phase I/II dose escalation trial in patients with solid tumor cancers, including non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers; IMC-F106C, which is in a Phase I/II dose escalation trial in patients with multiple solid tumor cancers comprising NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. In addition, the company''s programs for infectious diseases include IMC-I109V, which is in a Phase I/II clinical trial in patients with chronic hepatitis B virus; and IMC-M113V that is in pre-clinical development stage for patients with human immunosuppression virus. Further, it develops product candidates to provide precision targeted immunosuppression for the treatment of autoimmune diseases. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

Latest shares articles

Nvidia results preview: what to expect from Q3 after the AI sell-off
Revenue guidance of USD 108bn, a new interim CEO and an AI sell-off: what investors are watching as Nvidia reports its fiscal Q3 2027 results.
12:06, 17 November 2026
What you need to know about Alphabet after the biggest one-day drop in its history – break-down
Google Cloud is growing fast, but AI spending pushed Alphabet’s free cash flow negative. A full break-down of results, valuation, debt and risks for GOOGL
11:53, 13 November 2026
Amazon's USD 220bn bet: how record AI spending could reshape the company
Amazon plans about USD 220bn of capex in 2026. We look at AWS, profitability, debt, valuation and the key catalysts and risks for AMZN shares.
10:50, 6 November 2026
Wall Street sign beside the marble facade of the New York Stock Exchange building, with American flags flying from the exterior
US midterms: the end of uncertainty could give Wall Street direction
Markets dislike uncertainty and volatility tends to rise ahead of the vote, but once the results are known, indices may be able to set a clearer direction.
13:28, 29 October 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready